Company intelligence / Profile preview

UltraDx Bio

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

UD-X™ Analyzer received first clinical registration approval in China (NMPA) in August 2024, offering fg/ml sensitivity in trace protein biomarker detection, with initial application in early Alzheimer's diagnosis; companion assay kits pending approval.

Therapeutic areas: CardiovascularImmunologyInfectious DiseasesNeurologyOncology
Modalities: DevicePlatform technology (Single-Molecule Array Fluorescence Immunoassay Analyzer)
Industry: Protein Biomarker Diagnostics

Partnerships

Quanterix (collaboration for Simoa® technology and commercialization in China)ARCH Venture Partners (investor and strategic supporter)GF Hong Kong (investor and strategic supporter)

Beyond the preview

Go deeper on UltraDx Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UltraDx Bio.

Explore the full profile